Pharmaron Beijing Co., Ltd. (SHE:300759)
China flag China · Delayed Price · Currency is CNY
40.90
-0.70 (-1.68%)
Nov 17, 2026, 3:04 PM CST

Pharmaron Beijing Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Operating Revenue
15,99114,07312,26911,53310,2407,419
Other Revenue
21.921.96.44.6126.1924.48
16,01314,09512,27611,53810,2667,444
Revenue Growth
18.23%14.82%6.39%12.39%37.92%45.00%
Cost of Revenue
10,6229,2058,0917,4226,5024,768
Gross Profit
5,3914,8904,1844,1163,7642,676
Selling, General & Admin
2,2512,0431,8431,8591,7281,022
Research & Development
635.41576.02469.26448.28282.32151.77
Other Operating Expenses
182.95145.95109.782.7566.5244.04
Operating Expenses
3,1462,8452,4652,4262,0981,229
Operating Income
2,2442,0451,7191,6901,6671,448
Interest Expense
-202.54-192.81-243.72-182.19-167.31-83.07
Interest & Investment Income
84.3239.39615.778.95109.74371.99
Currency Exchange Gain (Loss)
2.652.6531.43147-42.39-3.16
Other Non Operating Income (Expenses)
-142.65-5.32-4.22-3.61-2.54-1.39
EBT Excluding Unusual Items
1,9861,8892,1181,7301,5641,732
Impairment of Goodwill
---73.54---
Gain (Loss) on Sale of Investments
15.48-35.971.5418.7568.09119.59
Gain (Loss) on Sale of Assets
-12.19-20-33.67-9.15-15.3-4.25
Asset Writedown
3.8-----
Other Unusual Items
128.379.3778.5198.4849.563.73
Pretax Income
2,1221,9132,0911,8381,6661,911
Income Tax Expense
423.08357.52377.1256.11314.25290.92
Earnings From Continuing Operations
1,6991,5551,7141,5821,3521,620
Minority Interest in Earnings
71.53108.7179.1919.3222.4740.95
Net Income
1,7701,6641,7931,6011,3751,661
Net Income to Common
1,7701,6641,7931,6011,3751,661
Net Income Growth
17.04%-7.22%12.01%16.48%-17.24%41.68%
Shares Outstanding (Basic)
1,8041,7621,7701,7721,7741,781
Shares Outstanding (Diluted)
1,8191,7711,7731,7751,7761,820
Shares Change
2.95%-0.11%-0.11%-0.05%-2.40%1.97%
EPS (Basic)
0.980.941.010.900.780.93
EPS (Diluted)
0.970.941.010.900.770.91
EPS Growth
13.69%-7.12%12.13%16.54%-15.21%38.94%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Free Cash Flow
-282.94551.97536.02-111.78-807.04-34.78
Free Cash Flow Per Share
-0.160.310.30-0.06-0.45-0.02
Dividend Per Share
0.2000.2000.2000.2000.2000.200
Dividend Growth
0%0%0%0%0%50.04%
Gross Margin
33.66%34.70%34.09%35.67%36.67%35.95%
Operating Margin
14.02%14.51%14.01%14.64%16.23%19.45%
Profit Margin
11.05%11.80%14.61%13.88%13.39%22.31%
Free Cash Flow Margin
-1.77%3.92%4.37%-0.97%-7.86%-0.47%
EBITDA
3,3473,0522,5972,4312,2271,852
EBITDA Margin
20.90%21.65%21.16%21.07%21.70%24.88%
D&A For EBITDA
1,1031,007878.18741.2560.76404.64
EBIT
2,2442,0451,7191,6901,6671,448
EBIT Margin
14.02%14.51%14.01%14.64%16.23%19.45%
Effective Tax Rate
19.94%18.69%18.03%13.94%18.86%15.22%
Revenue as Reported
16,01314,09512,27611,53810,2667,444